Recent

% | $
Quotes you view appear here for quick access.

Taro Pharmaceutical Industries Ltd. Message Board

  • imho_dyodd imho_dyodd Jun 9, 2014 6:28 AM Flag

    onychomycosis - valeant

    valean'ts product is nothing great. yet they are expecting peak $800m sales. If novexatin passes clinical trials it will cannibalize the whole market

    We acquired Jublia® through our purchase of Dow Pharmaceutical Sciences in 2008 and advanced Jublia® from pre-IND stage through Clinical Phases 1, 2 and 3," said J. Michael Pearson, chairman and chief executive officer. "We are working quickly to get this important product launched in the U.S. and Canada in the third quarter of 2014. We anticipate favorable managed care coverage in the U.S., similar to other branded antifungal agents, with peak sales of $300-$800 million in the U.S. alone and we are also working with other regulatory agencies around the world on further approvals. This is the fourth product, sourced from our acquisition of Dow Pharmaceutical Sciences, for which we have received FDA approval the other three being 1% clindamycin and 5% benzoyl peroxide gel (IDP 111), Acanya® and Retin-A Micro (tretinoin) Gel microsphere 0.08%. We have also filed a new treatment for acne, Onexton", which has a PDUFA date of November 30, 2014. All these compounds came through our Dow acquisition, bringing with it the full set of R&D capabilities from preclinical through regulatory."

 
TARO
144.99-0.36(-0.25%)Apr 17 4:07 PMEDT